Atorvastatin in stroke: a review of SPARCL and subgroup analysis

Statin therapy in patients with cardiovascular disease is associated with reduced incidence of stroke. The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transient ischemic attack (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Huisa, Branko N, Stemer, Andrew B, Zivin, Justin A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856578/
https://www.ncbi.nlm.nih.gov/pubmed/20407630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856578/
https://www.ncbi.nlm.nih.gov/pubmed/20407630

Ejemplares similares